Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG003 Plus Toripalimab vs Toripalimab as Neoadjuvant Therapy for HNSCC
NCT07677475Phase 2Not yet recruiting
- Sponsor
- Dongguan People's Hospital
- Start
- Aug 2026
- Primary completion
- Jan 2029
- Countries
- 1
01
Overview
A Phase 2 trial of becotatug vedotin in head and neck squamous cell carcinoma (HNSCC), sponsored by Dongguan People's Hospital. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
becotatug vedotin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07677475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07677475.